
News|Articles|June 20, 2024
Emerging Biosimilars and the Importance of Identifying Experienced Providers
Author(s)PurpleLab
Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year. Read more about how Biologics and Biosimilars help fight chronic disease as well as the difference between Generics and Biosimilars.
Trending on Applied Clinical Trials Online
1
FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data
2
Beyond Patient Centricity: What Rare Disease Research Gets Right
3
Fortrea to Acquire Worldwide Clinical Trials' Early Phase Services Division in $45 Million Deal
4
AI Moves Patient Recruitment from Trial Bottleneck to Competitive Edge: A 2026 Perspective
5